ALLOB
-
Biologics
Bone Therapeutics to strategically focus on lead cell therapy product ALLOB
REGULATED INFORMATION Strategic focus revised and fully focused on achieving topline results of the ALLOB Phase IIb study in tibial…
Read More » -
Biologics
Bone Therapeutics and Link Health sign a non-binding term sheet for the global rights of ALLOB
REGULATED INFORMATION Link Health to be granted global rights for development, manufacturing and commercialization of ALLOB Bone Therapeutics to receive…
Read More » -
Biologics
Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study
Gosselies, Belgium, 12 January 2020, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet…
Read More » -
Biologics
Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion
Gosselies, Belgium, 14 October 2020, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet…
Read More » -
Biologics
Bone Therapeutics, Link Health and Pregene to develop and commercialize the ALLOB allogeneic bone cell therapy platform in China and Southeast Asia
Gosselies, Belgium, 5 October 2020, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet…
Read More » -
Biologics
Bone Therapeutics’ allogeneic cell therapy product, ALLOB, meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion procedure
June 13, 2019 / Source: Bone Therapeutics SA Regulated Information – Inside Information Treatment with ALLOB resulted in significant clinical and radiological improvementsTreatment with…
Read More » -
Biologics
Bone Therapeutics SA announces final results from Phase I/IIA ALLOB delayed-union fracture study
Gosselies, Belgium, 14 September 2018, 7 am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company…
Read More » -
Biologics
Bone Therapeutics SA : Announces all Patients Meet Primary Endpoint in ALLOB® Phase I/IIA Delayed-Union Study Interim Analysis
Gosselies, Belgium, 20 September 2017, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing…
Read More » -
Hospitals
Bone Therapeutics announces further positive efficacy in ALLOB® Phase I/IIA delayed-union fracture trial
May 17, 2016 BONE THERAPEUTICS (Brussels:BOTHE) (Paris:BOTHE) (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high…
Read More » -
Spine
Bone Therapeutics completes recruitment of its ALLOB® Phase IIA spinal fusion study
BONE THERAPEUTICS, (Brussels:BOTHE) (Paris:BOTHE) (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in…
Read More » -
Biologics
Bone Therapeutics: ALLOB® Delayed-Union Program Awarded at Cells Orthopedics Conference
BONE THERAPEUTICS (Brussels:BOTHE) (Paris:BOTHE), the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair…
Read More » -
Spine
Bone Therapeutics Treats First Patients in Pioneering Trial for Minimally Invasive Treatment of Failed Spinal Fusion
BONE THERAPEUTICS (Brussels:BOTHE) (Paris:BOTHE), the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair and…
Read More »